Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.

Quanjie LI; Dongrong YI; Xiaobo Lei; Jianyuan Zhao; Yongxin Zhang; Xiangling Cui; Xia Xiao; Tao Jiao; Xiaojing Dong; Xuesen Zhao; Hui Zeng; Chen Liang; Lili Ren; Fei Guo; Xiaoyu LI; Jianwei Wang; Shan Cen

Return

Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.

Author: Quanjie LI ¹ ; Dongrong YI ¹ ; Xiaobo LEI ² ; Jianyuan ZHAO ¹ ; Yongxin ZHANG ¹ ; Xiangling CUI ¹ ; Xia XIAO ² ; Tao JIAO ² ; Xiaojing DONG ² ; Xuesen ZHAO ³ ; Hui ZENG ³ ; Chen LIANG ⁴ ; Lili REN ² ; Fei GUO ² ; Xiaoyu LI ¹ ; Jianwei WANG ² ; Shan CEN ¹
Author Information

1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical School, Beijing 100050, China.
2. Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical School, Beijing 100730, China.
3. Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
4. Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.
Publication Type:Journal Article
Keywords: Corilagin; Drug combinations; Non-nucleoside inhibitor; RdRp; SARS-CoV-2; Structure-based virtual screening; Viral replication
From: Acta Pharmaceutica Sinica B 2021;11(6):1555-1567
CountryChina
Language:English
Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become one major threat to human population health. The RNA-dependent RNA polymerase (RdRp) presents an ideal target of antivirals, whereas nucleoside analogs inhibitor is hindered by the proofreading activity of coronavirus. Herein, we report that corilagin (RAI-S-37) as a non-nucleoside inhibitor of SARS-CoV-2 RdRp, binds directly to RdRp, effectively inhibits the polymerase activity in both cell-free and cell-based assays, fully resists the proofreading activity and potently inhibits SARS-CoV-2 infection with a low 50% effective concentration (EC